SEATTLE, WASHINGTON – Sound Pharmaceuticals will present new preclinical and clinical data on SPI-1005 at the upcoming Association for Research in Otolaryngology (ARO) MidWinter Meeting in Orlando, FL. The company will deliver four presentations highlighting advancements in hearing loss and tinnitus research, including findings on ebselen’s potential to reverse noise-induced tinnitus and SPI-1005’s efficacy in Meniere’s disease treatment.
Presentations at ARO MidWinter Meeting:
- “Ebselen Permanently Reverses Noise-Induced Tinnitus in Young and Older Mice with Age-Related Hearing Loss” – Feb. 25 at 9:45 AM ET
- “SPI-1005 Improves Auditory and Vestibular Deficits in Meniere’s Disease in a Multi-Center Phase 3 Randomized Placebo-Controlled Trial (STOPMD-3)” – Feb. 23 at 4:45 PM ET
- “Ebselen-Eluting Silicone Strips Reduce Low Frequency Hearing Loss in a Guinea Pig Model of Cochlear Implantation” – Feb. 24 at 1:30-3:00 PM ET
Additionally, Sound Pharmaceuticals will present at the Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium, organized by the Defense Health Agency (DHA) Hearing Center of Excellence (HCE):
- “The Development of SPI-1005 for the Treatment of Hearing Loss and Tinnitus” – Feb. 21 at 1:00-5:00 PM ET
About the STOPMD-3 Trial
STOPMD-3, one of the largest and longest-running clinical trials for Meniere’s disease, screened 254 participants across 11 sites in the U.S. A total of 221 patients were randomized to receive SPI-1005 (400 mg twice daily for 28 days) or placebo, with follow-up extending to 12 months in some participants.
Dr. Paul Lambert, Distinguished University Professor and Chair Emeritus of the Department of Otolaryngology-HNS at MUSC, led the trial along with Dr. Shaun Nguyen, Director of Clinical Trial Research at MUSC. The trial builds on a successful Phase 2b study investigating SPI-1005’s role in treating Meniere’s disease symptoms, including hearing loss and vestibular dysfunction.
About SPI-1005
SPI-1005 is an investigational drug containing ebselen, a selenorganic compound that mimics glutathione peroxidase (GPx) activity, a key factor in reducing neuroinflammation in the inner ear, brain, retina, lungs, and kidneys. The drug is under investigation for several neurotologic conditions, including noise-induced hearing loss, ototoxicity from aminoglycosides and chemotherapy, and sensorineural hearing loss.
About Sound Pharmaceuticals
Sound Pharmaceuticals is a privately-held biotechnology company developing SPI-1005 for multiple neurotologic conditions. The company is actively conducting clinical trials on the prevention and treatment of aminoglycoside-induced ototoxicity (co-funded by the Cystic Fibrosis Foundation) and hearing preservation in cochlear implant patients (co-funded by MED-EL).
Source: Sound Pharmaceuticals
